Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 10 records in total 161
    records per page

    Performance SERO of SARS-CoV-2 Serology tests: Are they good enough?

    Authors: Isabelle Piec; Emma English; Mary Anette Thomas; Samir Darvisevic; William Duncan Fraser; William Garry John; Kyeong-Cheol Shin; June Hong Ahn; Sang Hyun Park; Srishti Basu; Soumi Chatterjee; Deboshmita Banerjee; Ishita Roy; Arup Kumar Mitra; Yasunori Watanabe; Max Crispin; David C Wraith; Adam F Cunningham; Mark T Drayson; Alex G Richter; Vera Lucia Garcia Calich; Otavio Cabral-Marques; Ana Tereza R de Vasconcelos; Praful Pandey; Santosh KN; Shitij Chaudhary; Vishakh C Keri; Vishal Singh Chauhan; Niranjan Mahishi; Anand Shahi; Ragu R; Baidhnath Gupta; Richa Aggarwal; Kapil Dev Soni; Neeraj Nischal; Manish Soneja; Sanjeev Lalwani; Chitra Sarkar; Randeep Guleria; Naveet Wig; Anjan Trikha

    doi:10.1101/2020.11.13.20229625 Date: 2020-11-16 Source: medRxiv

    Background In the emergency of the SARS-CoV-2 pandemic, great efforts were made to quickly provide serology testing to the medical community however, these methods have been introduced into clinical practice without the complete validation usually required by the regulatory organizations. Methods SARS-CoV-2 patient samples (n=43) were analysed alongside pre-pandemic control specimen (n=50), confirmed respiratory infections MESHD (n=50), inflammatory polyarthritis MESHD (n=22) and positive for thyroid stimulating immunoglobulin (n=30). Imprecision, diagnostic sensitivity SERO and specificity and concordance were evaluated on IgG serologic assays from EuroImmun, Epitope Diagnostics (EDI), Abbott Diagnostics and DiaSorin and a rapid IgG/IgM test SERO from Healgen. Results EDI and EuroImmun imprecision was 0.02-14.0% CV. Abbott and DiaSorin imprecision (CV) ranged from 5.2% - 8.1% and 8.2% - 9.6% respectively. Diagnostic sensitivity SERO of the assays were 100% (CI: 80-100%) for Abbott, EDI and EuroImmun and 95% (CI: 73-100%) for DiaSorin at [≥]14 days post PCR. Only the Abbott assay had a diagnostic specificity of 100% (CI: 91-100%). EuroImmun cross-reacted in 3 non- SARS-CoV-2 respiratory infections MESHD and 2 controls. The DiaSorin displayed more false negative results and cross-reacted in six cases across all conditions tested. EDI had one cross-reactive sample. The Healgen rapid test SERO showed excellent sensitivity SERO and specificity. Overall, concordance of the assays ranged from 76.1% to 97.9%. Conclusions Serological tests SERO for SARS-CoV-2 showed good analytical performance SERO. The head-to-head analysis of samples revealed differences in results that may be linked to the use of nucleocapsid or spike proteins. The point of care device tested demonstrated adequate performance SERO for antibody SERO detection.

    SARS-CoV-2 IgG antibody SERO responses in rt-PCR positive cases: first report from India

    Authors: Girish Chandra Dash; Debaprasad Parai; Hari Ram Choudhary; Annalisha Peter; Usha Kiran Rout; Rashmi Ranjan Nanda; Srikanta Kanungo; Jaya Singh Kshatri; Subrata Kumar Palo Sr.; Sanghamitra Pati; Dr. Debdutta Bhattacharya; Leo James; Jakob luptak; Guinevere L Grice; Soraya Ebrahimi; Xiaoli Xiong; John AG Briggs; Sumita Pai; angalee nadesalingham; Marie-Christine Ouellet; Marc-André Roy; Marie-Christine Saint-Jacques; Claudia Savard

    doi:10.1101/2020.11.13.20229716 Date: 2020-11-13 Source: medRxiv

    The SARS-CoV-2 antibody SERO responses remain poorly understood and the clinical utility of serological testing SERO is still unclear. As it is thought to confer some degree of immunity, this study is carried out to know the relationship between demographics and ct value of confirmed rt-PCR patients. A total of 384 serum samples SERO were collected between 4-6 weeks after confirmed SARS-CoV-2 infection MESHD. IgG positivity was found to be 80.2% (95% CI, 76.2 - 84.2). The positivity increased with the decrease in the ct value, with a highest of 87.6% positivity in individual with <20 ct value. The mean (SD) ct value of IgG positives and negatives was 23.34 (+/-6.09) and 26.72 (+/- 7.031) respectively. There was no significant difference found between the demographic characteristics such as age TRANS, sex, symptoms and antibody SERO response. The current study is first of its kind wherein we have assessed the correlation of ct of RT-PCR with development of IgG against SARS-CoV-2. Our study showed that although Ct value might not have any relation with severity of the diseases but is associated with the antibody SERO response among the SARS-CoV-2 infected MESHD individual.

    SARS-CoV-2 epitope mapping on microarrays highlights strong immune-response to N protein region

    Authors: Angelo Musicò; Roberto Frigerio; Alessandro Mussida; Luisa Barzon; Alessandro Sinigaglia; Silvia Riccetti; Federico Gobbi; Chiara Piubelli; Greta Bergamaschi; Marcella Chiari; Alessandro Gori; Marina Cretich

    doi:10.1101/2020.11.09.374082 Date: 2020-11-09 Source: bioRxiv

    A workflow for SARS-CoV-2 epitope MESHD discovery on peptide microarrays is herein reported. The process started with a proteome-wide screening of immunoreactivity based on the use of a high-density microarray followed by a refinement and validation phase on a restricted panel of probes using microarrays with tailored peptide immobilization through a click-based strategy. Progressively larger, independent cohorts of Covid-19 MESHD positive sera were tested in the refinement processes, leading to the identification of immunodominant regions on SARS-CoV-2 Spike MESHD (S), Nucleocapsid (N) protein and Orf1ab polyprotein. A summary study testing 50 serum samples SERO highlighted an epitope of the N protein (region 155-171) providing 92% sensitivity SERO and 100% specificity of IgG detection in Covid-19 MESHD samples thus being a promising candidate for rapid implementation in serological tests SERO.

    Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

    Authors: Lidia Oostvogels; Peter Kremsner; Andrea Kreidenweiss; Isabel Leroux-Roels; Geert Leroux-Roels; Arne Kroidl; Mirjam Schunk; Christoph Schindler; Jacobus Bosch; Rolf Fendel; Julian J Gabor; Thirumalaisamy P Velavan; Philipp Mann; Lisa Walz; Stefan Mueller; Oliver Schoenborn-Kellenberger; Thomas Verstraeten; Mariola Fotin-Mleczek; Dominik Vahrenhorst; Gianluca Quintini; Olaf-Oliver Wolz

    doi:10.1101/2020.11.09.20228551 Date: 2020-11-09 Source: medRxiv

    There is an urgent need for vaccines to counter the COVID-19 MESHD pandemic due to infections with severe HP acute respiratory syndrome coronavirus (SARS-CoV-2 MESHD). Evidence from convalescent sera and preclinical studies has identified the viral Spike (S) protein as a key antigenic target for protective immune responses. We have applied an mRNA-based technology platform, RNActive(R), to develop CVnCoV which contains sequence optimized mRNA coding for a stabilized form of S protein encapsulated in lipid nanoparticles (LNP). Following demonstration of protective immune responses against SARS-CoV-2 in animal models we performed a dose-escalation phase 1 study in healthy 18-60 year-old volunteers. This interim analysis shows that two doses of CVnCoV ranging from 2 g to 12 g per dose, administered 28 days apart were safe. No vaccine-related serious adverse events were reported. There were dose-dependent increases in frequency and severity of solicited systemic adverse events, and to a lesser extent of local reactions, but the majority were mild or moderate and transient in duration. Immune responses when measured as IgG antibodies SERO against S protein or its receptor-binding domain (RBD) by ELISA SERO, and SARS-CoV-2-virus neutralizing antibodies SERO measured by micro-neutralization, displayed dose-dependent increases. Median titers measured in these assays two weeks after the second 12 g dose were comparable to the median titers observed in convalescent sera from COVID-19 MESHD patients. Seroconversion (defined as a 4-fold increase over baseline titer) of virus neutralizing antibodies SERO two weeks after the second vaccination occurred in all participants who received 12 g doses. Preliminary results in the subset of subjects who were enrolled with known SARS-CoV-2 seropositivity at baseline show that CVnCoV is also safe and well tolerated in this population, and is able to boost the pre-existing immune response even at low dose levels. Based on these results, the 12 g dose is selected for further clinical investigation, including a phase 2b/3 study that will investigate the efficacy, safety, and immunogenicity of the candidate vaccine CVnCoV.

    Seroprevalence SERO of Anti- SARS-CoV-2 Antibodies SERO in a Cohort of New York City Metro Blood SERO Donors using Multiple SARS-CoV-2 Serological Assays SERO: Implications for Controlling the Epidemic and Reopening.

    Authors: Daniel K Jin; Daniel J Nesbitt; Jenny Yang; Haidee Chen; Julie Horowitz; Marcus Jones; Rianna Vandergaast; Timothy Carey; Samantha Reiter; Stephen J Russell; Christos Kyratsous; Andrea Hooper; Jennifer Hamilton; Manuel Ferreira; Sarah Deng; Donna Straus; Aris Baras; Christopher D Hillyer; Larry L Luchsinger; Claudia Romina Contreras; Andrew P Cope; Claudia De La Cruz; Paola Di Meglio; Paolo Gisondi; Kimme Hyrich; Denis Jullien; Jo Lambert; Hoseah Waweru; Helena Marzo-Ortega; Iain McInnes; Luigi Naldi; Sam Norton; Lluis Puig; Phyllis Spuls; Raj Sengupta; Tiago Torres; RIchard B Warren; John Weinman; Christopher EM Griffiths; Jonathan N Barker; Matthew A Brown; James B Galloway; Catherine H Smith

    doi:10.1101/2020.11.06.20220087 Date: 2020-11-07 Source: medRxiv

    Projections of the stage of the Severe Acute Respiratory Syndrome-Coronavirus-2 MESHD (SARS-CoV-2) pandemic and local, regional and national public health policies designed to limit the spread of the epidemic as well as reopen cities and states, are best informed by reproducible, high throughput, and statically credible antibody SERO (Ab) assays. To date, a myriad of Ab tests, both available and authorized for emergency use by the FDA, has led to confusion MESHD confusion HP rather than insight per se. The present study reports the results of a rapid, point-in-time 1,000-person cohort study using serial blood SERO donors in the New York City metropolitan area (NYC) using multiple serological tests SERO, including enzyme-linked immunosorbent assays SERO ( ELISAs SERO) and high throughput serological assays SERO (HTSAs). These were then tested and associated with assays for neutralizing Ab (NAb). Of the 1,000 NYC blood SERO donor samples in late June and early July 2020, 12.1% and 10.9% were seropositive using the Ortho Total Ig and the Abbott IgG HTSA assays, respectively. These serological assays SERO correlated with neutralization activity specific to SARS-CoV-2. The data reported herein suggest that seroconversion in this population occurred in approximately 1 in 8 blood SERO donors from the beginning of the pandemic in NYC (considered March 1, 2020). These findings deviate with an earlier seroprevalence SERO study in NYC showing 13.7% positivity. Collectively however, these data demonstrate that a low number of individuals have serologic evidence of infection during this first wave and suggest that the notion of herd immunity at rates of ~60% or higher are not near. Furthermore, the data presented herein show that the nature of the Ab-based immunity is not invariably associated with the development of NAb. While the blood SERO donor population may not mimic precisely the NYC population as a whole, rapid assessment of seroprevalence SERO in this cohort and serial reassessment could aid public health decision making.

    Analytical assessment of Beckman Coulter Access anti-SARS-CoV-2 IgG immunoassay SERO

    Authors: Maurizio Ruscio; Elisa D'Agnolo; Anna Belgrano; Mario Plebani; Giuseppe Lippi; Robab Breyer-Kohansal; Otto C Burghuber; Sylvia Hartl; Daniel Aletaha; Daniela Sieghart; Peter Quehenberger; Rodrig Marculescu; Patrick Mucher; Astrid Radakovics; Robert Strassl; Gerda Leitner; Oswald F Wagner; Christoph J Binder; Helmuth Haslacher; Asutosh Chilkoti

    doi:10.1101/2020.11.05.20226555 Date: 2020-11-07 Source: medRxiv

    Background. The approach to diagnosing, treating and monitoring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD relies strongly on laboratory resources, with serological testing SERO representing the mainstay for studying the onset, nature and persistence of humoral immune response. This study was aimed at evaluating the analytical performance SERO of the novel Beckman Coulter anti-SARS-CoV-2 IgG chemiluminescent immunoassay SERO. Methods. This analytical assessment encompassed the calculation of intra-assay, inter-assay and total imprecision, linearity, limit of blank (LOB), limit of detection (LOD), functional sensitivity SERO, and comparison of anti- SARS-CoV-2 antibodies SERO values obtained on paired serum samples SERO using DiaSorin Liaison SARS-CoV-2 S1/S2 IgG and Roche Elecsys Anti-SARS-CoV-2 total antibodies SERO. Diagnostic performance SERO was also tested against results of molecular testing on nasopharyngeal swabs, collected over the previous 4 months. Results. Intra-assay, inter-assay and total imprecision of Beckman Coulter anti-SARS-CoV-2 IgG were between 4.3-4.8%, 2.3-3.9% and 4.9-6.2%, respectively. The linearity of the assay was excellent between 0.11-18.8 antibody SERO titers. The LOB, LOD and functional sensitivity SERO were 0.02, 0.02 and 0.05, respectively. The diagnostic accuracy (area under the curve; AUC) of Beckman Coulter anti-SARS-CoV-2 IgG compared to molecular testing was 0.87 (95% CI, 0.84-0.91; p<0.001) using manufacturer's cut-off, and increased to 0.90 (95% CI, 0.86-0.94; p<0.001) with antibody SERO titers. The AUC was non-significantly different from that of Roche Elecsys Anti-SARS-CoV-2, but was always higher than that of DiaSorin Liaison SARS-CoV-2 S1 MESHD/S2 IgG. The correlation of Beckman Coulter Access SARS-CoV-2 IgG was 0.80 (95% CI, 0.75-0.84; p<0.001) with Roche Elecsys Anti-SARS-CoV-2 and 0.72 (95% CI, 0.66-0.77; p<0.001) with DiaSorin Liaison SARS-CoV-2 S1 MESHD/S2 IgG, respectively. Conclusions. The results of this analytical evaluation of Beckman Coulter Access anti-SARS-CoV-2 IgG suggests that this fully-automated chemiluminescent immunoassay SERO represents a valuable resource for large and accurate seroprevalence SERO surveys.

    Characteristics of three different chemiluminescence assays for testing for SARS-CoV-2 antibodies SERO

    Authors: Myriam Weber; Martin Risch; Sarah Thiel; Kirsten Grossmann; Susanne Nigg; Nadia Wohlwend; Thomas Lung; Dorothea Hillmann; Michael Ritzler; Francesca Ferrara; Susanna Bigler; Konrad Egli; Thomas Bodmer; Mauro Imperiali; Yacir Salimi; Felix Fleisch; Alexia Cusini; Sonja Heer; Harald Renz; Matthias Paprotny; Philipp Kohler; Pietro Vernazza; Lorenz Risch; Christian R. Kahlert; Benny Chain; Mahdad Noursadeghi; James C Moon

    doi:10.1101/2020.11.05.20225003 Date: 2020-11-06 Source: medRxiv

    Several tests based on chemiluminescence immunoassay SERO techniques have become available to test for SARS CoV 2 antibodies SERO. There is currently insufficient data on serology assay performance SERO beyond 35 days after symptoms onset TRANS. We aimed to evaluate SARS CoV 2 antibody SERO tests on three widely used platforms. A chemiluminescent microparticle immunoassay SERO (CMIA; Abbott Diagnostics, USA), a luminescence immunoassay SERO (LIA; Diasorin, Italy), and an electrochemiluminescence immunoassay SERO (ECLIA; Roche Diagnostics, Switzerland) were investigated. In a multigroup study, sensitivity SERO was assessed in a group of participants with confirmed SARS CoV MESHD 2 (n=145), whereas specificity was determined in two groups of participants without evidence of COVID 19 (i.e. healthy blood SERO donors, n=191, and healthcare workers, n=1002). Receiver operating characteristic (ROC) curves, multilevel likelihood ratios (LR), and positive (PPV) and negative (NPV) predictive values were characterized. Finally, analytical specificity was characterized in samples with evidence of Epstein Barr virus MESHD ( EBV MESHD) (n=9), cytomegalovirus ( CMV MESHD) (n=7) and endemic common cold coronavirus infections MESHD (n=12) taken prior to the current SARS CoV 2 pandemic. The diagnostic accuracy was comparable in all three assays (AUC 0.98). Using the manufacturers cutoffs, the sensitivities SERO were 90%, 95% confidence interval,[84,94] (LIA), 93% [88,96] (CMIA), and 96% [91,98] (ECLIA). The specificities were 99.5% [98.9,99.8]( CMIA) 99.7% [99.3,99,9] (LIA) and 99.9% [99.5,99.98] (ECLIA). The LR at half of the manufacturers cutoffs were 60 (CMIA), 82 (LIA), and 575 (ECLIA) for positive and 0.043 (CMIA) and 0.035 (LIA, ECLIA) for negative results. ECLIA had higher PPV at low pretest probabilities than CMIA and LIA. No interference with EBV MESHD or CMV infection MESHD was observed, whereas endemic coronavirus in some cases provided signals in LIA and/or CMIA. Although the diagnostic accuracy of the three investigated assays is comparable, their performance SERO in low prevalence SERO settings is different. Introducing gray zones at half of the manufacturers cutoffs is suggested, especially for orthogonal testing approaches that use a second assay for confirmation.

    Rapid homogeneous assay for detecting antibodies SERO against SARS-CoV-2

    Authors: Juuso Rusanen; Lauri Kareinen; Lev Levanov; Sointu Mero; Sari H Pakkanen; Anu Kantele; Fatima Amanat; Florian Krammer; Klaus Hedman; Olli Vapalahti; Jussi Hepojoki; Zenab Khan; Adriana Van de Guchte; Jayeeta Dutta; Lisa Miorin; Thomas Kehrer; Nicolas Galarce; Leonardo Almonacid; Jorge Levican; Harm van Bakel; Adolfo Garcia-Sastre; Rafael A. Medina; Lindsey J Waddoups; Lisa J Weaver; Elizabeth Zimmerman; Robert Paine III

    doi:10.1101/2020.11.01.20224113 Date: 2020-11-04 Source: medRxiv

    Accurate and rapid diagnostic tools are needed for management of the ongoing coronavirus disease MESHD coronavirus disease 2019 MESHD ( COVID-19 MESHD) pandemic. Antibody tests SERO enable detection of individuals past the initial phase of infection and will help to examine possible vaccine responses. The major targets of human antibody SERO response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are the spike glycoprotein (S) and nucleocapsid protein (N). We have developed a rapid homogenous approach for antibody SERO detection termed LFRET (protein L-based time-resolved Forster resonance energy transfer immunoassay SERO). In LFRET, fluorophore-labeled protein L and antigen are brought to close proximity by antigen-specific patient immunoglobulins of any isotype, resulting in TR-FRET signal generation. We set up LFRET assays for antibodies SERO against S and N and evaluated their diagnostic performance SERO using a panel of 77 serum SERO/ plasma SERO samples from 44 individuals with COVID-19 MESHD and 52 negative controls. Moreover, using a previously described S construct and a novel N construct, we set up enzyme linked immunosorbent assays SERO ( ELISAs SERO) for antibodies SERO against SARS-CoV-2 S MESHD and N. We then compared the LFRET assays with these enzyme immunoassays SERO and with a SARS-CoV-2 microneutralization test (MNT). We found the LFRET assays to parallel ELISAs SERO in sensitivity SERO (90-95% vs. 90-100%) and specificity (100% vs. 94-100%). In identifying individuals with or without a detectable neutralizing antibody SERO response, LFRET outperformed ELISA SERO in specificity (91-96% vs. 82-87%), while demonstrating an equal sensitivity SERO (98%). In conclusion, this study demonstrates the applicability of LFRET, a 10-minute 'mix and read' assay, to detection of SARS-CoV-2 antibodies SERO.

    Household Transmission TRANS of SARS-COV-2: Insights from a Population-based Serological Survey

    Authors: Qifang Bi; Justin Lessler; Isabella Eckerle; Stephen A Lauer; Laurent Kaiser; Nicolas Vuilleumier; Derek AT Cummings; Antoine Flahault; Dusan Petrovic; Idris Guessous; Silvia Stringhini; Andrew S Azman; - SEROCoV-POP; Claudia Ress; Caren Sourij; Lars Stechemesser; Harald Stingl; Thomas Stulnig; Norbert Tripolt; Michael Wagner; Peter Wolf; Andreas Zitterl; Susanne Kaser

    doi:10.1101/2020.11.04.20225573 Date: 2020-11-04 Source: medRxiv

    Importance: Knowing the transmissibility TRANS of asymptomatic TRANS infections and risk TRANS of infection from household and community exposures is critical to SARS-CoV-2 control. Limited previous evidence is based primarily on virologic testing, which disproportionately misses mild and asymptomatic TRANS infections. Serologic measures are more likely to capture all previously infected individuals. Objective: Estimate the risk of SARS-CoV-2 infection MESHD from household and community exposures, and identify key risk factors for transmission TRANS and infection. Design: Household serosurvey and transmission TRANS model. Setting: Population-based serosurvey in Geneva, Switzerland Participants: 4,524 household members five years and older from 2,267 households enrolled April-June 2020. Exposures: SARS-CoV-2 infected MESHD (seropositive) household members and background risk of community transmission TRANS. Main outcomes and measures: Past SARS-CoV-2 infection MESHD infection confirmed TRANS through anti-SARS-CoV-2 IgG antibodies SERO by ELISA SERO. Chain-binomial models based on the number of infections within households were used to estimate extra-household infection risk TRANS by demographics and reported extra- household contacts TRANS, and infection risk TRANS from exposure to an infected household member by demographics and infector's symptoms MESHD. Infections attributable to exposure to different types of infectious individuals were estimated. Results: The chance of being infected by a single SARS-CoV-2 infected MESHD household member was 17.2% (95%CrI 13.6-21.5%) compared to a cumulative extra-household infection risk TRANS of 5.1% (95%CrI 4.5-5.8%). Infection risk TRANS from an infected household member increased with age TRANS, from 7.5% (95%CrI 1.3-20.3%) among 5-9 years to 30.2% (95%CrI 14.3-48.2%) among those [≥]65 years. Working- age TRANS adults TRANS (20-49 years) had the highest extra-household infection risk TRANS. Seropositive household members not reporting symptoms had 74.8% lower odds (95%CrI 43.8-90.3%) of infecting another household member compared to those reporting symptoms, accounting for 19.6% (95%CrI 12.9-24.5%) of all household infections. Conclusions and Relevance: The risk of infection TRANS from exposure to a single infected household member was four-times that of extra-household exposures over the first wave of the pandemic. Young children TRANS had a lower risk from infection TRANS from household members. Asymptomatic TRANS infections are far less likely to transmit than symptomatic ones but do cause infections. While the small households in Geneva limit the contribution of household spread, household transmission TRANS likely plays a greater role in other settings.

    A household case evidences shorter shedding of SARS-CoV-2 in naturally infected cats compared to their human owners.

    Authors: Victor Neira Ramirez; Barbara Brito; Belen Aguero; Felipe Berrios; Valentina Valdes; Alberto Gutierrez; Naomi Ariyama; Patricio Espinoza; Patricio Retamal; Edward C Holmes; Ana Gonzalez-reiche; Zenab Khan; Adriana Van de Guchte; Jayeeta Dutta; Lisa Miorin; Thomas Kehrer; Nicolas Galarce; Leonardo Almonacid; Jorge Levican; Harm van Bakel; Adolfo Garcia-Sastre; Rafael A. Medina; Lindsey J Waddoups; Lisa J Weaver; Elizabeth Zimmerman; Robert Paine III

    doi:10.1101/2020.10.31.20220608 Date: 2020-11-04 Source: medRxiv

    Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) has been detected in domestic and wild cats. However, little is known about natural viral infections of domestic cats, although their importance for modeling disease spread TRANS, informing strategies for managing positive human-animal relationships and disease prevention. Here, we describe the SARS-CoV-2 infection MESHD in a household of two human adults TRANS and sibling cats (one male TRANS and two females TRANS) using real-time RT-PCR, an ELISA SERO test, viral sequencing, and virus isolation. On May 5th, 2020, the cat-owners tested positive for SARS-CoV-2. Two days later, the male TRANS cat showed mild respiratory symptoms and tested positive. Four days after the male TRANS cat, the two female TRANS cats became positive, asymptomatically TRANS. Also, one human and one cat showed antibodies SERO against SARS-CoV-2. All cats excreted detectable SARS-CoV-2 RNA for a shorter duration than humans and viral sequences analysis confirmed human-to-cat transmission TRANS. We could not determine if cat-to-cat transmission TRANS also occurred.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.